Table 2.
Demographics for people with RRMS with complete data at M0 (baseline) and follow-up (M12). DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale score; ICV: intracranial volume; WML: white matter lesions.
| Magnetisation transfer imaging | NODDI ISOVF / ICVF & g-ratio | |
|---|---|---|
| n (F:M) | 62 (48:14) | 60 (46:14) |
| Mean age [range] in years at M0 | 37.6 [21.7 to 67.3] | 37.8 [22.3 to 67.3] |
| Median EDSS at M0 [range] | 2 [0 to 6] | 2 [0 to 6] |
| Median EDSS at M12 [range] | 2.5 [0 to 6.5] | 2.75 [0 to 6.5] |
| Number of patients with DMT initiated by M12 | 38 (61.3 %) | 36 (60.0 %) |
| Mean number of days between diagnosis and M0 [range] | 68 [7 to 171] | 69 [8 to 171] |
| Median time since physician-reported first symptom onset in years [range] | 3.6 [0.2 to 33.2] (2 missing) | 3.55 [0.2 to 33.2] (2 missing) |
| Median WML volume (as % of ICV) at M0 [range] | 0.572 [0.041 to 2.628] |
0.572 [0.041 to 2.628] |
| Median change in WML volume over 1 year (as % of ICV, abs. diff) [range] | 0.165 [0.028 to 0.592] | 0.165 [0.028 to 0.592] |